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Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammatory 
disease characterized by incompletely reversible airway obstruction. This clinically hetero-
geneous group of patients is characterized by different phenotypes. Spirometry and clinical 
parameters, such as severity of dyspnea and exacerbation frequency, are used to diagnose and 
assess the severity of COPD. The purpose of this study was to investigate whether volatile 
organic compounds (VOCs) could be detected in the exhaled breath of patients with COPD 
and whether these VOCs could distinguish COPD patients from healthy subjects. Moreover, we 
aimed to investigate whether VOCs could be used as biomarkers for classifying patients into 
different subgroups of the disease. Ion mobility spectrometry was used to detect VOCs in the 
exhaled breath of COPD patients. One hundred and thirty-seven peaks were found to have a 
statistically significant difference between the COPD group and the combined healthy smokers 
and nonsmoker group. Six of these VOCs were found to correctly discriminate COPD patients 
from healthy controls with an accuracy of 70%. Only 15 peaks were found to be statistically 
different between healthy smokers and healthy nonsmokers. Furthermore, by determining the 
cutoff levels for each VOC peak, it was possible to classify the COPD patients into breathprint 
subgroups. Forced expiratory volume in 1 second, body mass index, and C-reactive protein seem 
to play a role in the discrepancies observed in the different breathprint subgroups.
Keywords: breath analysis, COPD, ion mobility spectrometry, volatile organic compounds
Introduction
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable 
disease worldwide and is one of the leading causes of morbidity and mortality. COPD 
is characterized by persistent limitation of airflow due to an abnormal inflammatory 
response of the lungs to the inhalation of noxious particles and gases and is mainly 
caused by cigarette smoking. The limitation of airflow is best measured by spirometry, 
which is widely available and reproducible.1 However, the lung function parameters 
obtained from spirometry do not always yield assessments of airway inflammation and 
severity of disease. Dyspnea and rate of exacerbations are essential for investigating 
the underlying mechanisms of the disease and for assessing severity of the disease and 
the response to the therapy.2 Furthermore, some subjects are not compliant enough to 
provide a good spirometry test; therefore, there is a need for additional methods that 
provide more information about the disease than airway limitation.3
Noninvasive methods, including the analysis of exhaled breath, have been studied 
in the past decades for their applicability in the assessment of airway inflammation and 
as possible diagnostic tools in several inflammatory lung diseases. A large number of 
biomarkers in breath have been investigated as possible indicators of inflammation, 
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to diagnose and monitor the disease as well as to evaluate the 
response to treatment. Exhaled breath is known to contain 
many volatile organic compounds (VOCs) at very low con-
centrations (nanomolar [10 9] or picomolar [10-12]).4,5 These 
VOCs may be products of various inflammatory and meta-
bolic processes, either physiological or disease-related, that 
take place in the airways and other parts of the human body, 
or products of the oxidative stress that occurs in diseases such 
as asthma and COPD.6,7 Therefore, the detection of VOCs 
in the exhaled breath is an attractive method to investigate 
possible biomarkers for diagnosing, monitoring, and assess-
ing the oxidative stress of various lung diseases.5,8 Previous 
studies have shown that a profile of VOCs could be used 
as a biomarker in lung cancer,9,10 asthma,11,12 sarcoidosis,13 
tuberculosis,14 and obstructive sleep apnea syndrome.15,16 
Profiles of exhaled VOCs provide fingerprints of diseases, the 
so-called “breathprints,” allowing for discriminating between 
patients and healthy subjects, without the need for chemical 
identification of the underlying substances.
Nowadays, many techniques are available to collect and 
analyze VOCs, such as the electronic nose (eNose), gas 
chromatography (GC) followed by either mass spectrometry 
(GCMS) or flame ionization detection (GC-FID), proton 
transfer reaction mass spectrometry (PTR-MS), selected ion 
flow tube mass spectrometry (SIFT-MS), laser spectroscopy, 
colorimetric sensor array and gold nanoparticle sensors 
(GNPs).17 Exhaled VOCs detected by gas chromatography–
mass spectrometry have been shown to discriminate patients 
with asthma or COPD from healthy subjects;18,19 as well as 
patients with COPD from patients with asthma or lung cancer 
with the use of the electronic nose.11,20 Ion mobility spec-
trometry (IMS) has been used in several studies for detecting 
VOCs in patients with several lung diseases.13,21,22 IMS is a 
new, on-site method, rapid and easy to use for detecting and 
separating VOCs according to their detection time, drift time, 
and their concentration in the exhaled breath. Moreover, IMS 
enables the visualization of VOCs in a three-dimensional 
topography, the so-called IMS chromatograph.23,24
The purpose of this study was to detect in the exhaled breath 
of patients with COPD VOCs that could be used as biomarkers 
in the diagnosis of the disease. Furthermore, we aimed to detect 
VOCs that could be used as possible biomarkers for classifying 
patients into different subtype groups of the disease.
Methods
study subjects
The patients included in the study were recruited from the 
Department of Pneumology, Ruhrlandklinik, University 
Hospital of Essen, Germany. Patients had an established diag-
nosis of COPD according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines.1 All patients 
had a history of smoking (20 pack per years) and an irre-
versible limitation of airflow (reversibility 12% predicted 
forced expiratory volume in 1 second [FEV
1
] and 200 mL 
in FEV
1
) after inhalation of β
2
-agonist. Patients were asked 
for comorbidities and in case of other existing respiratory and 
inflammatory diseases or malignancies, they were excluded 
from the study. All patients had no signs of acute exacerba-
tion for at least 4 weeks prior to enrollment.
The control groups consisted of healthy smokers and 
nonsmokers, and all were employees of the hospital. All 
healthy subjects had no history of respiratory disease and 
underwent lung function measurements to exclude obstruc-
tive lung disease. The nonsmoking subjects had a smoking 
history of less than two packs per year and had stopped 
smoking for at least 1 year. The study was approved by the 
ethics committee of the University of Essen and all subjects 
provided written informed consent.
study design
All VOC measurements were performed with the same ion 
mobility spectrometer device, in the same room and at the 
same daytime to avoid biased variations. The study par-
ticipants were requested to refrain from eating, drinking, and 
smoking for 2 hours prior to the measurement. All subjects 
underwent a medical history review, a physical examination, 
and a collection of breath air. Repeated measurements on the 
same day were performed in a subgroup of the healthy subjects 
to assess the within-day repeatability of the measurements.
lung function tests
The lung function tests were performed by a trained lung 
function technician using Zan500 Body (nSpire Health, 
Oberthulba, Germany) according to the American Thoracic 
Society/European Respiratory Society recommendations.25
Collection of exhaled breath
All subjects were requested to exhale through a mouthpiece 
connected via a Teflon tube with the spectrometer. In each 
case, end-tidal breath, controlled by a flow sensor, was col-
lected in a sample loop of 10 mL in volume. The sample 
air was collected and transferred to a multicapillary column 
for a first chromatographic separation. Using the software 
VOCan 1.3 (B&S Analytik, Dortmund, Germany), the dead 
volume was adjusted and fixed to 500 mL. The expiration 
was controlled by an ultrasound CO
2
 sensor element.
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analysis of exhaled breath
The IMS coupled to the multicapillary column (MCC/IMS) 
was a BioScout (B&S Analytik), consisting of the MCC/IMS 
and a SpiroScout (GanhornMedizin Electronic, Niederlauer, 
Germany) as a sample inlet unit. The major parameters of 
this setup are summarized elsewhere.24,26 In this spectro-
meter, a 550 MBq 63Ni β-radiation source was applied for 
the ionization of the carrier gas (air). The spectrometer 
was connected to a polar, multicapillary column (MCC, 
type OV-5; Multichrom Ltd, Novosibirsk, Russia) that was 
used as the preseparation unit. In this MCC, the analytes of 
exhaled breath were sent through 1,000 parallel capillaries, 
each with an inner diameter of 40 μm and a film thickness 
of 200 nm. The total diameter of the separation column was 
3 mm. The relevant MCC parameters are listed in Table 1.
Data mining and evaluation
The peaks were characterized using the software Visual Now 
(B&S Analytik), which is described elsewhere.27,28 All peaks 
found are characterized by their positions with respect to drift 
time (corresponding 1/K
0
 value), retention time, and their 
concentration in relation to the peak height.22,28
statistical analysis
The statistical analysis was performed using SPSS 
(version 17.0). The normality of distributions was evaluated 
with the Kolmogorov–Smirnov test. The comparisons among 
groups were performed with one-way analysis of variance 
for normally distributed data and with the Kruskal–Wallis 
test for skewed data, with appropriate post hoc tests to adjust 
for multiple comparisons (Bonferroni). The difference of a 
numerical variable between two groups was evaluated with 
an unpaired t-test or Mann–Whitney U-tests for normal and 
skewed data, respectively.
Furthermore, a classification model was constructed using 
twofold cross-validation. The training data were randomly 
split in two parts: one to develop the model and one to mea-
sure its performance.
Results
The subjects’ characteristics are summarized in Table 2. 
Breath analysis was performed on 45 COPD patients (aged 
56.2±8.5 years), 23 healthy smokers (aged 38.7±14 years) 
and 28 healthy nonsmokers (aged 42.5±8.4 years). There were 
no significant differences in sex and body mass index (BMI) 
among the three groups. The COPD patients had a heavier 
smoking history than the healthy smokers (33±14 packs per 
year vs 18.6±18 packs per year).
The mean FEV
1
 (predicted percentage) in patients with 
COPD was 28.3±18.9 vs 105.6±8.0 in healthy smokers and 
97±14 in healthy nonsmokers. The severity of COPD was 
GOLD IV (n=21), GOLD III (n=16), GOLD II (n=5), and 
GOLD I (n=3). Patients were referred to the Department of 
Pneumology, University Hospital of Essen, to examine the 
potential for endoscopic or surgical lung volume reduction 
or for their addition to the lung transplant waiting list.
Table 1 Characteristics of ion mobility spectrometer
Parameter Spectrometer
Ionization source 63ni (555 MBq) β-radiation
Electric field strength 320 V/cm
length of drift region 12 cm
Diameter of drift region 15 mm
length of ionization chamber 15 mm
shutter opening time 300 μs
shutter impulse time 100 ms
Drift gas synthetic air (20.5% O2,  
79.5% n2)
Drift gas flow 100 ml/min
Temperature ambient temperature
Pressure 101 kPa (ambient pressure)
MCC type OV-5, polar
Column temperature 40°C
Abbreviation: MCC, multicapillary column.
Table 2 Patients’ characteristics
Parameters COPD (n=45) Healthy smokers (n=23) Healthy nonsmokers (n=28) P-value
age (years) 56.2±8.5a,b 38.7±14 42.5±8.4 0.0001
sex (female/male) 27/18 14/9 14/14 ns
BMI (kg/m2) 25.7±6.8 25.4±4.6 25.4±4 ns
ex-smokers/current smokers 40/5a,b 12/11 0 0.01
smoking history (pack per years) 33±14b 18.6±18 0 ns
FeV1% (pred) 28.3±18.9a,b 105.6±8 97±14 0.0001
FeV1 (l) 0.89±0.73a,b 3.4±0.72 3.4±0.9 0.0001
FeV1/VC (pred) 35.3±20.5a,b 80.4±5 75.3±4 0.0001
Notes: aStatistically significant difference compared to healthy smokers; bstatistically significant difference compared to healthy nonsmokers.
Abbreviations: FeV1, forced expiratory volume in 1 second; VC, vital capacity; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ns, not significant; 
pred, predicted.
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A total of 224 VOC peaks were identified, as characterized 
by drift and retention times (Figure 1). The signal intensity of 
the peaks was statistically evaluated with the Wilcoxon rank 
sum test. One hundred and thirty-seven peaks were found to 
have a statistically significant difference between the COPD 
group and the combined healthy smokers and nonsmokers 
group. When the healthy smokers and the healthy nonsmok-
ers were compared with each other, only 15 peaks were found 
to be statistically different between the two groups (EES, EJ, 
FI, FL, FP, GF, P, PS 22, PS3, P1, P2, P27, P38, P4, and P40) 
(Supplementary information). Using 50:50 cross-validation, 
six peaks (PS0, PS14, PS47, P51, P52, and P2) from among 
the total of 137 (Figure 2) were found to correctly classify 
(with an accuracy of 71%, 70%, 70%, 71%, 70%, and 67%, 
respectively) the COPD patients from the healthy controls 
(smokers and nonsmokers combined).
For each peak, a cutoff value in signal intensity was deter-
mined such that the COPD patients were correctly classified as 
COPD and the healthy controls as non-COPD, with a specificity 
of 100%. Using this cutoff value for each peak, we examined 
if the COPD patients lie above or below this cutoff value. It 
becomes apparent that the vast majority of the patients (41 out 
of 45) have at least five out of the six peaks above or below this 
cutoff. When their peaks were found above the cutoff, it was 
defined as “typical COPD breathprint.” When the peaks were 
found to be below (again at least five of the six peaks), patients 
were defined as having “no typical COPD breathprint.”
In only four patients, no more than four peaks were in 
accordance to classify the patients into one of these two 
breathprint subgroups. These four patients were excluded from 
further analysis, which was performed to investigate the reason 
for these discrepancies. These four patients seemed to have 
no common characteristics in their breathprints. Thus, 23 of 
41 patients were classified as having a “typical COPD breath-
print” and 18 as not having a “typical COPD breathprint.”
To further investigate the possible reasons for the dis-
crepancies in the breathprints of these patients, we examined 
a set of clinical parameters that were likely to discriminate 
these two breathprint subgroups. From these parameters, the 
subgroup of patients with a “typical COPD breathprint” by 
VOC profile had statistically significant higher FEV
1
, BMI, 
and lower CRP in comparison with the subgroup without 
“typical COPD breathprint” by VOC profile (Table 3). For 
other parameters, no significant differences between the two 
subgroups could be found.
Discussion
Using IMS, we have shown that the VOC profile of the 
exhaled breath of COPD patients is different from that of 
healthy subjects. Six VOCs were found to classify and dis-
tinguish correctly the COPD patients from healthy subjects. 
Further, by using cutoff levels for each of the six VOC 
peaks, it was possible to discriminate the COPD patients 
into two breathprint subgroups, patients with a “typical 
COPD breathprint” and patients without a “typical COPD 
breathprint.”
The use of noninvasive techniques for assessing air-
way inflammation, such as the analysis of exhaled breath, 
has developed rapidly since nitric oxide was described as 
an important biomarker in the exhaled breath of asthma 
patients.29 Apart from nitric oxide, a large number of bio-
markers have been tested in exhaled breath with various 
noninvasive methods, such as induced sputum and exhaled 
breath condensate, to investigate, assess, and monitor airway 
inflammation or oxidative stress in lung diseases.30 These 
noninvasive diagnostic methods are very attractive for 
clinical settings also because they are easy to perform and 
safe for the patients. Furthermore, these noninvasive meth-
ods, in contrast to invasive methods, can be easily repeated 
and applied by patients with severe diseases.
Recent studies have also shown discrimination of COPD 
patients from healthy subjects using several methods for 
detecting VOCs in exhaled breath. Our findings are in 
accordance with the recent study of Basanta et al31 which 
discriminated COPD patients from healthy subjects with an 
accuracy of 69% using gas chromatography time-of-flight 
mass spectrometry. In a study by van Berkel et al19 using 
gas chromatography–mass spectrometry, six peaks were 
detected that classified correctly 92% of the patients with a 
sensitivity of 98% and a specificity of 88%. However, these 
two studies included a larger proportion of current smokers 
(31% and 76%, respectively) than was included in our study 
(13%). This higher proportion of smokers in these two studies 
could possibly explain the higher accuracy of discriminat-
ing COPD patients from healthy subjects compared to the 
results of our study. Phillips et al32 also showed using gas 
chromatography–mass spectrometry, in a large study group 
of 119 COPD patients and 63 healthy subjects, that VOCs 
can distinguish COPD patients from healthy subjects with a 
high accuracy of 74%. In their study, the COPD and control 
group were matched for age and BMI because these factors 
could possibly affect VOCs.32 In our study, no difference 
was found for BMI between the two groups, but age was 
statistically different between the two groups. While age is a 
possible factor affecting VOCs via oxidative stress, currently 
only few data provide support for this suggestion.33–35
The study of Phillips et al32 implies that smoking status 
influences the correct classification of COPD patients as 
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active smoking may be a confounding factor in the analysis 
of exhaled breath. Previous studies have shown that active 
smoking influences the VOC profile in exhaled breath.8,36,37 
However, when we compared healthy smokers with healthy 
nonsmokers in our study, 15 peaks that were found to dis-
tinguish the two groups were not similar to the peaks that 
distinguished COPD patients from healthy subjects (smoking 
and nonsmoking combined). Consequently, it is probable that 
smoking did not affect our results.
Identification of the underlying substances detected in the 
exhaled breath was beyond the scope of this investigation. 
Substance identification is not strictly necessary because IMS 
allows for the detection of VOC profiles that are themselves 
useful as potential markers for detecting disease without the 
need for further chemical analysis. A recent study could show 
using the electronic nose that VOCs could identify bacterial 
colonization in COPD patients.38 This could be a subject for 
a future study using the IMS. An interesting aspect of this 
study was that by identifying cutoff values for each of the 
six peaks that discriminated COPD patients from healthy 
subjects, these peaks were found to be unequally distributed 
among COPD patients. In contrast, COPD patients could 
be further classified into two breathprint subgroups: those 
with a “typical COPD breathprint” and those without a 
“typical COPD breathprint.” This finding implies that there 
are plausible subtypes within COPD patients and that these 
subtypes can be identified by breath analysis. This result 
is in accordance with the study of Basanta et al31 which 
Figure 2 Box-and-whisker plots of the six peaks P2, P51, P52, Ps0, Ps14, and Ps47 that differentiated the COPD patients from the healthy subjects (healthy smokers and 
healthy nonsmokers).
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Table 3 Clinical parameters of COPD patients with and without “typical COPD breathprint”
Clinical parameters Patients with “typical COPD  
breathprint” (n=23)
Patients without “typical  
COPD breathprint” (n=18)
P-value
FeV1 (% pred) 36.8±21 18.7±9 0.05
BMI (kg/m2) 27.6±8 22.8±4 0.05
CrP (mg/dl) 0.6±1 1.7±2 0.05
age (years) 58±11 54±6 0.140
serum creatinine (mg/dl) 0.82±0.2 0.78±0.2 0.789
Pack per years 32.6±18 32±11 0.946
pO2 (mmhg) 70.5±10 75.5±15 0.486
pCO2 (mmhg) 42.7±7 47.7±9 0.115
Abbreviations: FeV1, forced expiratory volume in 1 second; BMI, body mass index; CrP, C-reactive protein; COPD, chronic obstructive pulmonary disease; pred, 
predicted.
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showed that VOCs in exhaled breath identified clinically 
relevant subgroups, eg, COPD patients with sputum eosino-
philia, asymptomatic smokers, or patients with frequent 
exacerbations.
It is known that COPD is a complex and multidimen-
sional disease with different pulmonary and extrapulmonary 
manifestations.39 Although diagnosis and monitoring of the 
disease are based on lung function tests, it is now known that 
the measurement of FEV
1
 alone does not express the full 
complexity of the disease. Various phenotypes reflect several 
clinical, immunological, and inflammatory mechanisms of 
COPD that influence the outcome of the disease and the 
response to treatment.33,40
To elucidate the parameters that are associated with 
the discrepancy in classifying COPD patients by the VOC 
profiles identified in our study, we analyzed further the dif-
ferences in FEV
1
, BMI, CRP, age, serum creatinine, packs 
per year, pO
2
, and pCO
2
 between the two subgroups. Our 
finding that patients with lower FEV
1
 do not show a “typical 
COPD breathprint” may be explained by higher oxidative 
stress in a more severe stage of the disease. This suggestion 
could explain the finding that patients without “typical COPD 
breathprint” had lower BMI and higher CRP, indicators for 
systemic inflammation, which is more prominent in severe 
COPD. Another possible explanation could be that metabolic 
processes independent of inflammation influence the breath-
print of patients with more severe disease in a way that they 
have similarities with the breathprint of healthy subjects. 
Further characterization of these COPD patients using other 
inflammatory biomarkers or clinical data is of interest and 
should be investigated in further studies.
Our study has certain limitations. Repeated IMS measure-
ments were performed in healthy subjects on the same day, 
showing good reproducibility. However, reproducibility was 
not tested in COPD patients. It is suggested that sample vari-
ability and short-term effects of practice or exertion should 
be considered in breath analysis tests.41 Incalzi et al3 suggest 
that VOC patterns are reproducible in healthy subjects and 
patients with very severe COPD, whereas these are less 
reproducible in COPD patients with less severe disease. This 
finding may reflect hypoxemia, which characterizes these 
patients. As the majority of the patients measured in this study 
suffer from severe COPD, variability of IMS measurement 
might not be a confounding factor in our study. Another 
limitation of our study is that no information was collected 
regarding medication of the patients. Further studies are 
needed to test the possible effects of medication on exhaled 
breath and to test repeatability and reproducibility in COPD 
patients. Although identification of the underlying substances 
of the detected VOCs was beyond the interest of this study, 
this could be a subject of future studies that would probably 
reveal the origin of these compounds and further elucidate 
the pathophysiological mechanisms involved in the patho-
genesis of COPD.
Conclusion
In this study, it was shown that the identification of VOCs 
using IMS was able to distinguish COPD patients from 
healthy subjects. Two subgroups of COPD patients were 
identified according to their VOC breathprints. Further stud-
ies with larger sample size are needed to completely charac-
terize these subgroups, as well as to identify the underlying 
substances of the VOCs.
Acknowledgments
The authors thank Gabriele Kentrat (Ruhrlandklinik, Essen, 
Germany) for her assistance with data collection. This 
research has been supported by the “Deutsche Forschun-
gsgemeinschaft” within the Collaborative Research Center 
(“Sonderforschungsbereich”) SFB 876.
Disclosure
Baumbach JI has shares as inventor in diverse patents and is 
shareholder of a company that produces ion mobility spec-
trometers. The other authors report no conflicts of interest 
in this work.
References
1. Global Strategy for the Diagnosis, Management and Prevention of COPD. 
Global Initiative for Chronic Obstructive Lung Disease (COPD) Revised 
2014 [Internet]. Available from: http://www.goldcopd.org/
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagno-
sis, management, and prevention of chronic obstructive pulmonary 
disease: GOLD executive summary. Am J Respir Crit Care Med. 
2007;176(6):532–555.
3. Incalzi RA, Scarlata S, Pennazza G, Santonico M, Pedone C. Chronic 
obstructive pulmonary disease in the elderly. Eur J Intern Med. 
2014;25(4):320–328.
4. Phillips M. Method for the collection and assay of volatile organic 
compounds in breath. Anal Biochem. 1997;247(2):272–278.
5. Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of 
urine vapor and breath by gas-liquid partition chromatography. Proc 
Natl Acad Sci U S A. 1971;68(10):2374–2376.
6. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive 
pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care 
Med. 1997;156(2 pt 1):341–357.
7. MacNee W. Oxidative stress and lung inflammation in airways disease. 
Eur J Pharmacol. 2001;429(1–3):195–207.
8. Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: 
biomarkers of diseases. Biomed Chromatogr. 2007;21(6):553–566.
9. Phillips M, Cataneo RN, Cummin ARC, et al. Detection of lung cancer 
with volatile markers in the breath. Chest. 2003;123(6):2115–2123.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
406
Besa et al
10. Darwiche K, Baumbach JI, Sommerwerck U, Teschler H, Freitag L. 
Bronchoscopically obtained volatile biomarkers in lung cancer. Lung. 
2011;189(6):445–452.
11. Fens N, Roldaan AC, van der Schee MP, et al. External validation of 
exhaled breath profiling using an electronic nose in the discrimination 
of asthma with fixed airways obstruction and chronic obstructive pul-
monary disease. Clin Exp Allergy. 2011;41(10):1371–1378.
12. Meyer N, Dallinga JW, Nuss S, et al. Defining adult asthma endotypes by 
clinical features and patterns of volatile organic compounds in exhaled 
air. Respir Res. 2014;15(1):136.
13. Westhoff M, Litterst P, Freitag L, Baumbach JI. Ion mobility spec-
trometry in the diagnosis of sarcoidosis: results of a feasibility study. 
J Physiol Pharmacol. 2007;58(suppl 5, pt 2):739–751.
14. Phillips M, Cataneo RN, Condos R, et al. Volatile biomarkers 
of pulmonary tuberculosis in the breath. Tuberculosis (Edinb). 
2007;87(1):44–52.
15. Greulich T, Hattesohl A, Grabisch A, et al. Detection of obstructive sleep 
apnoea by an electronic nose. Eur Respir J. 2013;42(1):145–155.
16. Incalzi RA, Pennazza G, Scarlata S, et al. Comorbidity modulates non 
invasive ventilation-induced changes in breath print of obstructive sleep 
apnea syndrome patients. Sleep Breath. Epub 2014 Oct 17.
17. Van de Kant KDG, van der Sande LJTM, Jöbsis Q, van Schayck OCP, 
Dompeling E. Clinical use of exhaled volatile organic compounds in 
pulmonary diseases: a systematic review. Respir Res. 2012;13:117.
18. Ibrahim B, Basanta M, Cadden P, et al. Non-invasive phenotyping 
using exhaled volatile organic compounds in asthma. Thorax. 
2011;66(9):804–809.
19. van Berkel JJBN, Dallinga JW, Möller GM, et al. A profile of volatile 
organic compounds in breath discriminates COPD patients from con-
trols. Respir Med. 2010;104(4):557–563.
20. Dragonieri S, Annema JT, Schot R, et al. An electronic nose in the 
discrimination of patients with non-small cell lung cancer and COPD. 
Lung Cancer. 2009;64(2):166–170.
21. Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach J-I. Ion 
mobility spectrometry for the detection of volatile organic compounds 
in exhaled breath of patients with lung cancer: results of a pilot study. 
Thorax. 2009;64(9):744–748.
22. Westhoff M, Litterst P, Madulla S, et al. Differentiation of chronic 
obstructive pulmonary disease (COPD) including lung cancer patients 
from health control group by breath analysis using ion mobility spec-
trometry. Int J Ion Mobil Spectrom. 2010;13:131–139.
23. Baumbach JI, Eiceman GA. Ion mobility spectrometry: arriving on 
site and moving beyond a low profile. Appl Spectrosc. 1999;53(9): 
338A–355A.
24. Baumbach JI. Process analysis using ion mobility spectrometry. Anal 
Bioanal Chem. 2006;384(5):1059–1070.
25. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirom-
etry. Eur Respir J. 2005;26(2):319–338.
26. Jünger M, Bödeker B, Baumbach JI. Peak assignment in multi-capillary 
column-ion mobility spectrometry using comparative studies with gas 
chromatography-mass spectrometry for VOC analysis. Anal Bioanal 
Chem. 2010;396(1):471–482.
27. Boedeker B, Baumbach I. Analytical description of IMS signals. Int 
J Ion Mobil Spectrom. 2009;12:103–108.
28. Boedeker B, Vautz W, Baumbach J. Visualisation of MCC/IMS – data. 
Int J Ion Mobil Spectrom. 2008;11:77–82.
29. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, 
Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. 
Lancet. 1994;343(8890):133–135.
30. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am 
J Respir Crit Care Med. 2001;163(7):1693–1722.
31. Basanta M, Ibrahim B, Dockry R, et al. Exhaled volatile organic 
compounds for phenotyping chronic obstructive pulmonary disease: 
a cross-sectional study. Respir Res. 2012;13:72.
32. Phillips CO, Syed Y, Parthaláin NM, Zwiggelaar R, Claypole TC, Lewis KE. 
Machine learning methods on exhaled volatile organic compounds for 
distinguishing COPD patients from healthy controls. J Breath Res. 
2012;6(3):036003.
33. Phillips M, Cataneo RN, Greenberg J, Gunawardena R, Naidu A, 
Rahbari-Oskoui F. Effect of age on the breath methylated alkane con-
tour, a display of apparent new markers of oxidative stress. J Lab Clin 
Med. 2000;136(3):243–249.
34. Phillips M, Cataneo RN, Greenberg J, Gunawardena R, Rahbari-Oskoui F. 
Increased oxidative stress in younger as well as in older humans. Clin 
Chim Acta. 2003;328(1–2):83–86.
35. Moretti M, Phillips M, Abouzeid A, Cataneo RN, Greenberg J. Increased 
breath markers of oxidative stress in normal pregnancy and in preec-
lampsia. Am J Obstet Gynecol. 2004;190(5):1184–1190.
36. Jareño-Esteban JJ, Muñoz-Lucas MÁ, Carrillo-Aranda B, et al. Volatile 
organic compounds in exhaled breath in a healthy population: effect of 
tobacco smoking. Arch Bronconeumol. 2013;49(11):457–461.
37. Filipiak W, Ruzsanyi V, Mochalski P, et al. Dependence of exhaled 
breath composition on exogenous factors, smoking habits and exposure 
to air pollutants. J Breath Res. 2012;6(3):036008.
38. Sibila O, Garcia-Bellmunt L, Giner J, et al. Identification of airway 
bacterial colonization by an electronic nose in Chronic Obstructive 
Pulmonary Disease. Respir Med. 2014;108(11):1608–1614.
39. Agusti A, Calverley PMA, Celli B, et al. Characterisation of COPD 
heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
40. Vestbo J, Agusti A, Wouters EFM, et al. Should we view chronic 
obstructive pulmonary disease differently after ECLIPSE? A clini-
cal perspective from the study team. Am J Respir Crit Care Med. 
2014;189(9):1022–1030.
41. Phillips C, Mac Parthaláin N, Syed Y, Deganello D, Claypole T, Lewis K. 
Short-term intra-subject variation in exhaled volatile organic com-
pounds (VOCs) in COPD patients and healthy controls and its effect 
on disease classification. Metabolites. 2014;4(2):300–318.
